Q-omics provides the consensus-scored GSTA1 profile across patient tissues and cancer cell-line models. GSTA1 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, GSTA1 is differentially expressed in 13, with the highest sampling consensus in KIRP. Additionally, GSTA1 RNA expression shows 14,242 significant protein co-abundance associations, with the highest sampling consensus in HNSC. Together, these results highlight KIRC, KIRP, and HNSC as cancer lineages where GSTA1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for GSTA1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes GSTA1 survival associations across molecular data types. GSTA1 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible GSTA1 RNA expression–survival associations across cancer types. High GSTA1 expression shows unfavorable associations in STAD and LAML, but favorable associations in KIRC, ACC, LUSC and CESC. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for GSTA1 RNA expression.
This table summarizes GSTA1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13. The strongest signals are observed in KIRP for RNA.
This table ranks reproducible tumor–normal expression differences for GSTA1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. GSTA1 shows lower tumor expression in KIRP, KICH, COAD, BRCA and LUAD and higher tumor expression in KIRC. The KIRP box plot shows higher GSTA1 RNA expression in normal versus tumor tissue (log2 FC = −4.895, t-test p < 0.001).
This table shows molecular features associated with GSTA1 in patient tissues and cancer cell lines. In patient samples, GSTA1 shows the broadest associations at the RNA and protein expression levels, with HNSC recurring as the lineage with the largest associated feature set. In cancer cell lines, GSTA1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_SCLC, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Myeloma and LIVER.
